Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir prophylaxis after intensive immunosuppressive therapy in severe aplastic anemia
ChiCTR2600119374Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of letermovir in aplastic anemia and cytomegalovirus disease (CMV) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of clinically significant CMV infection and CMV disease within 12 weeks. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
letermovir
03
Conditions
aplastic anemiacytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR2600119374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119374.